Recent Updates
Recently added Catalysts
SRTS Positive Sentiment

Sensus Healthcare to Host First Quarter 2024 Financial Results and Business Update Conference Call on Thursday, May 9, 2024

Key Takeaway: Sensus Healthcare, a medical device company focused on non-invasive treatments, announced it will hold a conference call on May 9, 2024, to discuss its first quarter 2024 financial results. The call will also include updates on the company's business and milestones. Participants can register in advance to bypass live operators, and the call will be webcasted for broader accessibility. An archived version will be available post-call.
Price reaction · baseline $3.25 (2024-04-17 close) · hit after-hours · clean, no other SRTS news in the window
day 0 close
0%

Market Sentiment Analysis

POSITIVE FACTORS

  • Sensus Healthcare is set to discuss its financial results, indicating ongoing operations.
  • The company emphasizes innovative treatments for skin cancer and keloids.
  • Management will provide a business update regarding recent and upcoming milestones.

Full Press Release Details

BOCA RATON, Fla. , April 18, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, May 9, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
Participants are encouraged to pre-register for the conference call using this link. Upon registration participants will receive a unique dial in number that will permit them to bypass the live operator. Participants may pre-register at any time, including up to and after the call start time. Those without internet access or unable to pre-register may access the conference call by dialing, 1-844-481-2811 (U.S. and Canada Toll Free) or 1-412-317-0676 (International). Please direct the operator to be connected to the Sensus Healthcare conference call.
The call will be webcast live and can be accessed at this link, which also may be found in the Investor Relations section of the Company’s website at www.sensushealthcare.com.
Following the conclusion of the conference call, a telephone replay will be available until June 9th, and can be accessed by dialing 877-344-7529 (U.S. Toll Free), 855-669-9658 (Canada Toll Free), or 412-317-0088 (International).  At the system prompt, dial the replay code – 9785929 – followed by the # sign. Playback will automatically begin. An archived webcast of the call will also be available in the Investor Relations section of the Company’s website for a period of time.
About Sensus Healthcare, Inc.
Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings.
For more information, visit www.sensushealthcare.com.

Frequently Asked Questions

When will Sensus Healthcare hold its financial conference call?

The conference call is scheduled for May 9, 2024, at 4:30 p.m. Eastern.

How can I participate in the Sensus Healthcare call?

Participants can pre-register online or call 1-844-481-2811 for U.S. access.

Will the conference call be available for replay?

Yes, a replay will be available until June 9 by dialing 877-344-7529.

What technologies does Sensus Healthcare specialize in?

Sensus Healthcare specializes in non-invasive treatments using SRT technology.

Where can I find more information about Sensus Healthcare?

More information is available on their website at www.sensushealthcare.com.

Last updated: Apr 18, 2024